Published in Vaccine Weekly, December 18th, 2002
This randomized phase III study will test a personalized immunotherapy vaccine created from a patient's own tumor cells to potentially combat the cancer and interfere with disease progression. New York Weill Cornell is the only site in New York State participating in this trial.
"This study is for patients with previously untreated, advanced stage low-grade non-Hodgkin's lymphoma who want to use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.